|
CN111936468A
|
|
Compounds with anti-cancer activity
|
|
WO2019172420A1
|
|
Pharmaceutical composition
|
|
TW201920668A
|
|
Nucleic acid complex
|
|
TW201909925A
|
|
Nucleic acid complex
|
|
CN110959014A
|
|
Anti-human CCR1 monoclonal antibody
|
|
WO2018225873A1
|
|
Nucleic-acid-containing nanoparticles
|
|
WO2018225871A1
|
|
Compound serving as cationic lipid
|
|
TW201837172A
|
|
Nucleic acid capable of inhibiting expression of masp2
|
|
WO2018124189A1
|
|
Method of selecting cells
|
|
WO2018117253A1
|
|
Nucleic acid inhibiting expression of complement factor b
|
|
JP2018143232A
|
|
Production method for darbepoetin composition, and culture method for darbepoetin-producing cells
|
|
WO2018101448A1
|
|
Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
|
|
JP2018065789A
|
|
Cationic lipid
|
|
TW201813632A
|
|
Nucleic-acid-containing lipid nanoparticles
|
|
WO2018062233A1
|
|
Cationic lipid compound
|
|
MX2019002861A
|
|
Medicinal composition.
|
|
JP2019024444A
|
|
Nucleic acid conjugates
|
|
JP2018021909A
|
|
Fixing method
|
|
JP2018123114A
|
|
Liquid pharmaceutical compositions comprising darbepoietin
|
|
KR20190022832A
|
|
Nucleic acid complex
|
